



Micro-X Limited,  
1284 South Road, Tonsley,  
Clovelly Park, South Australia, 5042

ABN: 21 153 273 735

**Monday 26<sup>th</sup> June 2017**

**ASX Announcement – MICRO-X LIMITED (ASX: MX1)**

**Nano Commercialisation Update: Carestream receives FDA 510(k) Approval for Nano**

---

Micro-X Limited (ASX: MX1) is delighted to advise that its distribution partner, Carestream Health Inc., has received notification that the US Food and Drug Administration (FDA) has determined the substantial equivalence of the DRX Revolution Nano to the predicate device and thus may now market the product in the USA.

This is an historic first regulatory approval for a carbon nano-tube-powered x-ray product and marks the culmination of an intensive development program by Micro-X in close collaboration with Carestream Health.

“We are pleased and proud to have achieved this highly significant milestone in the Nano’s commercialisation program” commented Micro-X’s Managing Director, Peter Rowland. “Our focus now is on supporting Carestream’s upcoming trade trials and preparations for volume production at Tonsley with our supply chain partners”.

Carestream will be showing the DRX Revolution Nano at the AHRA meeting in Anaheim, California on July 9<sup>th</sup> <http://www.carestream.com/publicNewsEventsArticle.aspx?vertical=news&id=480510>

---

For further information please contact:

Mr Peter Rowland, Managing Director, Micro-X Limited

Telephone: +61 418 844 981 [prowland@micro-x.com](mailto:prowland@micro-x.com)  
[www.micro-x.com](http://www.micro-x.com)

**About Micro-X:** Micro-X Limited (“MX1”) is an Australian Securities Exchange listed company developing and commercialising a range of highly innovative products based on proprietary carbon nanotube emitter technologies exclusively licensed and sourced from XinRay Systems Inc., a US based technology developer. These technologies enable the miniaturisation of a number of X-ray applications relevant to large global markets.